



Supplementary Materials


A375 24 h




A375 48 h



A375 72 h










Figure S1. Viability of A375, C32 melanoma cells and dermal fibroblasts treated with compounds 1–37 or cisplatin for 24, 48 and 72 hours determined by a MTT assay. Data are presented as mean \pm SD from three independent experiments. * $p < 0.05$ compared to control group.








Figure S2. Viability of A375, C32 melanoma cells and dermal fibroblasts treated with compounds 1–37 or cisplatin for 24, 48 and 72 hours determined by a neutral red uptake assay. Data are presented as mean \pm SD from three independent experiments. * $p < 0.05$ compared to control group.




Figure S3. Quantitative analysis of western immunoblot images. Data are presented as mean \pm SD.
 * $p < 0.05$ compared to control group.




Figure S4. Quantitative analysis of immunofluorescence images. Data are presented as mean ± SD. * $p < 0.05$ compared to control group.




Figure S5. A375 cell line, RSK protein, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S6. A375 cell line, pRSK protein, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S7. A375 cell line, PARP and cPARP, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S8. A375 cell line, caspase 9, first band —control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S9. A375 cell line, caspase 8, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S10. A375 cell line, caspase 7, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S11. A375 cell line, caspase 3, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S12. A375 cell line, actin, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S13. C32 cell line, RSK, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S14. C32 cell line, pRSK, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S15. C32 cell line, PARP and cPARP, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S16. C32 cell line, caspase 9, first band —control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S17. C32 cell line, caspase 7, first band —control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S18. C32 cell line, caspase 3, first band —control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




Figure S19. C32 cell line, actin, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.